CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7,864 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04529122
NCT04529122N/ACompleted

A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)

Hoffmann-La Roche·observational·Posted Aug 27, 2020·Updated May 27, 2026

In Brief

An observational study for Solid Tumours. Completed, enrolled 7,864 participants across 136 sites in 32 countries.

Detailed Summary

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumours
CountriesArgentina, Austria, Brazil, Canada, Chile, Colombia, Egypt, Estonia, France, Germany, Greece, Hungary, India, Ireland, Israel, Lebanon, Mexico, Philippines, Poland, Portugal, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Taiwan, Thailand, Turkey (Türkiye), United Arab Emirates, United Kingdom, Vietnam
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 27, 2020
Enrollment StartAug 27, 2020
Primary CompletionApr 24, 2026
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 5.8 years ago